Clinical trials: Patient With Schizophrenia Spectrum Disorder
- Condition Patient With Schizophrenia Spectrum Disorder
- Funder type Industry (pharma, biotech, devices)
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
- Trial name
- NCT00216723
- Testing
- Aripiprazole
- Where
- 2 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT04825860
- Testing
- SEP-363856 50 mg, SEP-363856 75 mg
- Where
- 54 sites in China, Japan and 2 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Schizophrenia
Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.
The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when…
- Trial name
- NCT00828958
- Testing
- Risperidone long-acting injectable
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
The primary objective of this study is to evaluate the long-term safety and tolerability of paliperidone palmitate in Japanese patients with schizophrenia.
- Trial name
- NCT01258920
- Testing
- Paliperidone palmitate
- Where
- 29 sites in Japan
- Volunteers
- 201 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia, Schizoaffective Disorder
An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia
The purpose of this study is to estimate the level of symptomatic and psychosocial remission of patients with schizophrenia and schizoaffective disorder in standard clinical practice as a function of the degree of adherence to…
- Trial name
- NCT01309373
- Testing
- Patient assessment
- Volunteers
- 1,809 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Study of CYR-101 in Patients With Schizophrenia
This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients…
- Trial name
- NCT00861796
- Testing
- CYR-101
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Cyrenaic Pharmaceuticals
Schizophrenia
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
The purpose of this study is to evaluate the change of medication satisfaction measured by Medication Satisfaction Questionnaire (MSQ) from baseline to endpoint for patients who are switched into paliperidone palmitate, either…
- Trial name
- NCT01682161
- Testing
- Paliperidone palmitate
- Where
- 9 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Janssen Korea, Ltd., Korea
Psychosis
An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication.
- Trial name
- NCT00878462
- Testing
- Asenapine WHITE raspberry flavor (Treatment A), Asenapine RED raspberry flavor (Treatment B), Asenapine WHITE UNFLAVORED (Treatment C)
- Volunteers
- 174 people
- Sponsor
- Organon and Co
Schizophrenia
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
The objective of the study is to investigate the efficacy, safety and tolerability of four different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic…
- Trial name
- NCT02281773
- Testing
- BI 409306 100 mg QD, BI 498306 50 mg QD, BI 498306 25 mg QD
- Where
- 43 sites in United States, Canada and 3 more
- Volunteers
- 518 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Multicenter, Open-label, Safety and Tolerability Study
This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis.
- Trial name
- STEP 210 (NCT01649557)
- Testing
- OPC-34712
- Where
- 68 sites in United States, Bulgaria and 10 more
- Volunteers
- 244 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Schizophrenia
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of paliperidone palmitate 3 month formulation (PP3M) compared with placebo in delay of the time to first occurrence of relapse of the symptoms of schizophrenia.
- Trial name
- NCT01529515
- Testing
- PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq.
- Where
- 53 sites in United States, Colombia and 6 more
- Volunteers
- 509 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00159770
- Testing
- ziprasidone versus olanzapine , risperidone or quetiapine, Panss , CGI-C, UKU-SERS-Pa, Blood tests
- Where
- 43 sites in Denmark, Finland and 2 more
- Volunteers
- 290 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depression, Schizophrenia
Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
This is a research study comparing the safety and efficacy of two active study medications
- Conditions
- Depression, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00034801
- Testing
- olanzapine, ziprasidone
- Where
- 30 sites in United States
- Volunteers
- 378 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
This multicenter study assessed the effects of 24 weeks of basmisanil treatment on cognition and functioning of stable schizophrenia participants treated with antipsychotics.
- Trial name
- NCT02953639
- Testing
- Basmisanil
- Where
- 37 sites in United States
- Volunteers
- 214 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
The primary purpose of the study is to compare the rate of hospitalization associated with psychotic relapse in participants with schizophrenia treated one year before with oral antipsychotics and one year after with long acting…
- Trial name
- REALAI (NCT02712463)
- Where
- 11 sites in Brazil, Mexico
- Volunteers
- 310 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
The Management of Schizophrenia in Clinical Practice (MOSAIC)
This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform…
- Trial name
- NCT01746134
- Where
- 44 sites in United States
- Volunteers
- 557 people
- Sponsor
- Genentech, Inc.
Schizophrenia
Paliperidone Palmitate Flexible Dosing in Schizophrenia
This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or…
- Trial name
- PALMFlexS (NCT01281527)
- Testing
- Paliperidone Palmitate
- Where
- 127 sites in Austria, Belgium and 18 more
- Volunteers
- 1,044 people
- Sponsor
- Janssen-Cilag International NV